Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average recommendation of “Hold” by the eighteen brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $129.6875.

A number of equities research analysts recently commented on the company. Guggenheim increased their price target on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Stifel Nicolaus raised their target price on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Piper Sandler cut their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Launched TruPath Genome and unveiled a NovaSeq X roadmap at AGBT — new product roadmap and platform upgrades can drive future instrument sales and recurring consumable revenue, and management highlighted multiomics/cancer initiatives that improve long‑term growth visibility. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
• Positive Sentiment: Illumina Laboratory Services to provide clinical whole‑genome sequencing and interpretation to Florida State University’s pediatric rare disease lab — expands clinical lab services, supports adoption of clinical WGS, and helps generate recurring service revenue. Illumina whole‑genome sequencing technology to accelerate rare disease testing in Florida
• Positive Sentiment: Collaboration with Takara Bio on a single‑cell spatial transcriptomics workflow presented at AGBT — strengthens Illumina’s single‑cell and spatial offerings and complements the company’s multiomics strategy. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow
• Positive Sentiment: Market/flow-driven momentum: analysts and quant flows have turned more constructive after Illumina’s upbeat 2026 outlook and the completed SomaLogic deal — higher relative strength and above‑average volume are cited as drivers of today’s rally. Illumina jumps 5.5% as momentum builds after upbeat outlook and multiomics push
• Neutral Sentiment: Canaccord reiterated a Hold, noting competitive pressures but that 2026 revenue targets remain intact — keeps near‑term expectations cautious despite longer‑term roadmap. Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating
• Neutral Sentiment: Competitive context: comparisons to fast‑growing peers (e.g., Tempus) highlight execution risk and the need for Illumina to convert product and multiomics momentum into sustained top‑line growth. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Neutral Sentiment: Short‑interest data released today shows zero reported short shares (likely a reporting anomaly) and thus offers no clear bearish pressure signal at present.

Illumina Stock Up 5.5%

ILMN opened at $134.46 on Tuesday. The firm has a market cap of $20.56 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 2.57 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm’s 50-day simple moving average is $135.12 and its 200-day simple moving average is $118.26. Illumina has a twelve month low of $68.70 and a twelve month high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts anticipate that Illumina will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ILMN. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter valued at about $25,000. Board of the Pension Protection Fund bought a new stake in shares of Illumina in the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC raised its position in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new position in Illumina during the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in Illumina during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.